ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (80)
2024
-
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 695-702
-
Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74
2023
-
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
Genome Medicine, Vol. 15, Núm. 1
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194
-
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
European Journal of Cancer, Vol. 188, pp. 39-48
-
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505
2022
-
Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252] (European Journal of Cancer (2021) 154(246-252) (S0959804921004044), (10.1016/j.ejca.2021.06.029))
European Journal of Cancer
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670
-
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
-
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
The oncologist, Vol. 27, Núm. 4, pp. e328-e339
-
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors
Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167
2021
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
-
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
European Journal of Cancer, Vol. 154, pp. 246-252
-
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Scientific Reports, Vol. 11, Núm. 1
-
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
ESMO Open, Vol. 6, Núm. 2
-
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608